OMass Technologies Ltd.

https://www.omass.com

OMass Therapeutics is a private biopharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. *

	Start	2016-01-01 established (s-off)
	End	2018-11-21 renamed
	Group	OMass Therapeutics Ltd.
	Today	OMass Therapeutics Ltd.
	Predecessor	University of Oxford
	Successor	OMass Therapeutics Ltd.
	Industry	drug discovery
	Industry 2	mass spectrometry (MS)
	Person	Robinson, Carol (Univ Oxford 201004 Physical and Theoretical Chemistry Laboratory + OMass)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Heatley Road Oxford Science Park, The Schrödinger Building
	City	OX4 4GE Oxford, Oxfordshire
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: OMass Therapeutics Ltd.. (11/21/18). "Press Release: OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines". Oxford.

		Record changed: 2019-08-09

More documents for OMass Therapeutics Ltd.

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com